128 related articles for article (PubMed ID: 12387462)
1. Dose-response analysis of effects of tibolone on climacteric symptoms.
Landgren MB; Bennink HJ; Helmond FA; Engelen S
BJOG; 2002 Oct; 109(10):1109-14. PubMed ID: 12387462
[TBL] [Abstract][Full Text] [Related]
2. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day.
Landgren MB; Helmond FA; Engelen S
Maturitas; 2005 Mar; 50(3):222-30. PubMed ID: 15734603
[TBL] [Abstract][Full Text] [Related]
3. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
Kroiss R; Fentiman IS; Helmond FA; Rymer J; Foidart JM; Bundred N; Mol-Arts M; Kubista E
BJOG; 2005 Feb; 112(2):228-33. PubMed ID: 15663589
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
5. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms.
Hammar M; Christau S; Nathorst-Böös J; Rud T; Garre K
Br J Obstet Gynaecol; 1998 Aug; 105(8):904-11. PubMed ID: 9746385
[TBL] [Abstract][Full Text] [Related]
7. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
8. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
[TBL] [Abstract][Full Text] [Related]
9. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
10. Tibolone vaginal versus per os administration in the management of post-menopausal symptoms.
Zervoudis S; Iatrakis G; Peitsidis P; Tsikouras P; Galazios G; Liberis V; Navrozoglou I; Ceauşu I; Badiu C
Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):471-7. PubMed ID: 21491823
[TBL] [Abstract][Full Text] [Related]
11. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
12. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women.
Huber J; Palacios S; Berglund L; Hänggi W; Sathanandan SM; Christau S; Helmond F
BJOG; 2002 Aug; 109(8):886-93. PubMed ID: 12197367
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone.
Bai W; Henneicke-von Zepelin HH; Wang S; Zheng S; Liu J; Zhang Z; Geng L; Hu L; Jiao C; Liske E
Maturitas; 2007 Sep; 58(1):31-41. PubMed ID: 17587516
[TBL] [Abstract][Full Text] [Related]
14. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
15. The influence of tibolone on quality of life in postmenopausal women.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
Maturitas; 2002 Jan; 41(1):35-43. PubMed ID: 11809341
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial.
Morais-Socorro M; Cavalcanti MA; Martins R; Neto Francisco P; Rezende A; Azevedo G; Almeida M
Gynecol Endocrinol; 2012 Jun; 28(6):483-7. PubMed ID: 22132809
[TBL] [Abstract][Full Text] [Related]
17. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women.
Rymer J; Robinson J; Fogelman I
Climacteric; 2002 Dec; 5(4):390-8. PubMed ID: 12626219
[TBL] [Abstract][Full Text] [Related]
18. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
19. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints.
Egarter C; Huber J; Leikermoser R; Haidbauer R; Pusch H; Fischl F; Putz M
Maturitas; 1996 Feb; 23(1):55-62. PubMed ID: 8861087
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms].
Bai WP; Wang SY; Liu JL; Geng L; Hu LN; Zhang ZL; Chen SL; Zheng SR
Zhonghua Fu Chan Ke Za Zhi; 2009 Aug; 44(8):597-600. PubMed ID: 20003788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
